In contrast to these studies, in which hypermethylation of the IGFBP3 promoter is a common and early event during tumorigenesis, we found only 9/36 of HB tumor cases to be methylated, seven of which were high-risk metastatic tumors, indicating a late event in the development of HB. Here, IGFBP3 is linked to neoplasm.